At the 2014 American Diabetes Association Scientific Sessions, GI Dynamics presented study findings that demonstrated the acute effects of EndoBarrier Therapy on glycemic control, its ability to reduce dependence on diabetes medications, including insulin, as well as data that help explain its potential mechanism of action.

The EndoBarrier was evaluated in “The Acute Effect of EndoBarrier Treatment on Glucose Homeostasis in Obese Uncontrolled Diabetic Subjects,” for the effects on glucose homeostasis, HbA1c, weight loss, insulin requirements and appetite (n=33). Glucose levels were monitored continuously for 1 week beginning 2 days before the device placement.

RELATED: Novel Weight Loss Device Effective in BA Increase

A 29% drop in average daily glucose was seen within days post-implantation despite a reduction of 50% in insulin dose during this time. Patients also showed a significant reduction in both weight (-8.9kg) and HbA1c (-1.4%) levels, which led to lower insulin requirements. Weight loss was also accompanied by a decrease in appetite as measured by the visual analog scale.

The EndoBarrier device is currently being investigated in a multicenter clinical trial (The ENDO Trial) for the treatment of patients who have uncontrolled type 2 diabetes and are obese.

For more information visit